spironolactone has been researched along with Atheroma in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)." | 7.78 | Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012) |
| "The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)." | 3.78 | Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajagopalan, S | 1 |
| Alaiti, MA | 1 |
| Broadwater, K | 1 |
| Goud, A | 1 |
| Gaztanaga, J | 1 |
| Connelly, K | 1 |
| Fares, A | 1 |
| Shirazian, S | 1 |
| Kreatsoulas, C | 1 |
| Farkouh, M | 1 |
| Dobre, M | 1 |
| Fink, JC | 1 |
| Weir, MR | 1 |
| Raz-Pasteur, A | 1 |
| Gamliel-Lazarovich, A | 1 |
| Coleman, R | 1 |
| Keidar, S | 1 |
1 trial available for spironolactone and Atheroma
| Article | Year |
|---|---|
Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.
Topics: Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Clinical Protocols; Diabetes Mellitus, Type 2; Di | 2017 |
1 other study available for spironolactone and Atheroma
| Article | Year |
|---|---|
Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cytochrome P-450 CYP1 | 2012 |